Meeting Abstract

Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial


Authors listKhanna, Dinesh; Denton, Christopher; Spotswood, Helen; Jahreis, Angelika; van Laar, Jacob M.; Burke, Laura; Lin, Celia J. F.; Pope, Janet E.; Allanore, Yannick; Mueller-Ladner, Ulf; Siegel, Jeffrey; Furst, Daniel E.

Publication year2016

JournalArthritis & Rheumatology

Volume number68

ISSN2326-5191

eISSN2326-5205

ConferenceAnnual Meeting of the American-College-of-Rheumatology/Association-of-Rheumatology-Health-Professionals (ACR/ARHP)

PublisherWiley



Citation Styles

Harvard Citation styleKhanna, D., Denton, C., Spotswood, H., Jahreis, A., van Laar, J., Burke, L., et al. (2016) Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial, Arthritis & Rheumatology, 68

APA Citation styleKhanna, D., Denton, C., Spotswood, H., Jahreis, A., van Laar, J., Burke, L., Lin, C., Pope, J., Allanore, Y., Mueller-Ladner, U., Siegel, J., & Furst, D. (2016). Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial. Arthritis & Rheumatology. 68.


Last updated on 2025-02-04 at 01:44